



Washington State Health Care Authority
Prescription Drug Program
626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

February 12, 2024

Re: Solicitation for one physician to serve on the Washington State Pharmacy and Therapeutics Committee. Applications are due COB March 29, 2024.

Dear Interested Parties:

The Washington State Health Care Authority is seeking applications from interested physicians to fill one opening on the Washington State Pharmacy & Therapeutics (P&T) Committee beginning on June 1, 2024.

The purpose of the committee is to evaluate the available evidence of the relative safety, efficacy, and effectiveness of prescription drugs within a class of prescription drugs and make recommendations to the appointing authority for its deliberation in the development of the Washington preferred drug list established in RCW 70.14.050. The P&T Committee also serves as the Apple Health (Medicaid) Drug Utilization Review (DUR) Board. The DUR Board does a similar evaluation of drug classes for the Apple Health preferred drug list.

The initial term of appointment is 3 years. Members of the committee are expected to attend six full day meetings a year, with a few hours of reading to prepare for the meeting. Members of the committee will be compensated for attendance at meetings in accordance with a personal services contract executed after appointment to the committee.

Applicants should submit a **current CV or resume**, and fill out the [application](#) and [conflict of interest \(COI\)](#) form demonstrating that they meet the following criteria set forth in WAC 182-50-025:

- Members must be actively practicing in their clinical area of expertise at a physical location in Washington State throughout the entire term of their appointment.
- Members must have knowledge and expertise in one or more of the following:
 - Clinically appropriate prescribing of covered outpatient drugs;
 - Clinically appropriate dispensing and monitoring of covered outpatient drugs;
 - Drug use review;
 - Medical quality assurance;
 - Disease state management; or
 - Evidence-based medicine.
- Members of the committee shall not be employed by a pharmaceutical manufacturer, a pharmacy benefits management company, or by any state agency administering state purchased health care programs during their term and shall not have been so employed for eighteen months prior to their appointment.

- A member shall not have a substantial financial conflict of interest including any interest in any pharmaceutical company, including the holding of stock options or the receipt of honoraria or consultant moneys. The appointing authority in its sole discretion may disqualify any potential member if it determines that a substantial conflict of interest exists.
- As part of the application process, prospective committee members shall complete a conflict of interest disclosure form, provided by the appointing authority, and after appointment, annually by July 1st of each year. Members must keep their disclosure statements current and provide updated information whenever circumstances change.
- Applicants with state licensure actions or Medicaid/Medicare sanctions will be considered case-by-case.
- Committee members must agree to keep all proprietary information confidential.

Applications must be received no later than close of business March 29, 2024. Finalists will be interviewed by HCA.

Please submit application, CV, and COI to Leta Evaskus, leta.evaskus@hca.wa.gov. For more information, please contact Donna Sullivan, PharmD at (360) 725-1564, or donna.sullivan@hca.wa.gov.

Sincerely,



Donna Sullivan, Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority
[WPDP website](#)